Composition
Tab 15/30/45 mg: Dacomitinib 15/30/45 mg
Indications & Dosage
Non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations (specialist use only): Adult: 45 mg once daily, for dose adjustments, treatment interruption or discontinuation; consult product literature.
Precautions
Cardiac risk factors or conditions which may affect left ventricular ejection fraction; monitor ECG before starting treatment and monthly thereafter, indicative of interstitial lung disease or pneumonitis including dyspnoea, cough, and fever, avoid in severe hepatic impairment; monitor liver function periodically; interrupt treatment if severe changes in liver function occur, caution in severe renal impairment. Females of childbearing potential should use effective contraception during treatment and for at least 17 days after stopping treatment.
Pregnancy
Avoid
Lactation
Avoid. Discontinue breast-feeding
Side Effects
Alopecia, appetite decreased, asthenia, dehydration, diarrhoea, dry eye, dry mouth, eye in ammation, hypertrichosis, hypokalaemia, increased risk of infection, interstitial lung disease (discontinue permanently), mucositis, nail discolouration, nail disorders, nausea, oral disorders, Oropharyngeal pain, pneumonitis (discontinue permanently), skin reactions, taste altered, vomiting, weight decreased.